Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiNK Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on allogeneic iNKT cell therapies, including formal disclosures about agenT-797, program updates, operating results and financing activity. Current reports have covered quarterly and annual financial results, clinical and publication-related updates, potential strategic discussions, and an at-the-market common stock sales agreement registered under a shelf registration statement.
The company’s proxy and governance filings disclose annual meeting matters, director elections, auditor ratification, board appointments, officer designations and compensation-related items. Other filings describe its Nasdaq-listed common stock, equity incentive plan activity, intercompany services arrangements with Agenus for finance functions, and risk-sensitive updates related to clinical development, capital needs and public-company governance.
MiNK Therapeutics insider Jennifer Buell amended a previously reported Form 4 to disclose that 5,351 shares of common stock were withheld to cover withholding taxes related to stock issued to her on 09/09/2025. The amended entry shows those withheld shares were disposed at a price of $15.36, leaving the reporting person with 36,492 shares beneficially owned. The amendment corrects an omission in the original Form 4 that did not include the tax-withheld shares in Table I.
MiNK Therapeutics reported a change in its board of directors. On September 23, 2025, the company’s Board elected Dr. John Holcomb as a Class II director, with his initial term ending at the 2026 annual meeting of stockholders. This adds new expertise to the board without changing its overall structure.
In connection with his election, Dr. Holcomb received a stock option to purchase 4,174 shares of MiNK common stock under the 2021 Equity Incentive Plan and the non-employee director compensation program. The option has a 10-year term, an exercise price set at the closing market price on the grant date, and vests in three equal annual installments as long as he continues to serve. As a non-employee director, he is also eligible for cash and potential additional equity compensation under the same program.
MiNK Therapeutics insider grant: Chief Executive Officer Jennifer Buell received 18,229 shares of common stock and a stock option to purchase 50,000 shares on September 9, 2025, as part of her 2024 performance bonus. The issued shares were valued at $15.36 per share on the grant date and are fully vested on issuance but subject to a lockup that releases 100% on October 9, 2025. The option has an exercise price of $15.36, vests over three years (one-third at the first anniversary, then eight equal quarterly installments) and expires September 9, 2035. Following the transactions, Buell beneficially owned 41,913 shares and held 50,000 options.
MiNK Therapeutics director Robert Peter Kadlec was granted a stock option to buy 3,225 shares of common stock at an exercise price of $15.36 per share on 09/09/2025. The option is an award that vests in full on the one-year anniversary of the grant date if Mr. Kadlec remains on the board and expires on 09/09/2035. The Form 4 was filed for the reporting person identified at a New York address and signed by an attorney-in-fact on 09/11/2025. No cash proceeds were reported at the time of filing.
MiNK Therapeutics director Peter Behner was granted a stock option on 09/09/2025 to buy 3,225 shares of common stock at an exercise price of $15.36 per share. The option was reported on Form 4 filed 09/11/2025 and is exercisable through 09/09/2035. The option vests in full on the one-year anniversary of the grant date provided Mr. Behner continues to serve on the company's board through that date. Following the grant, Mr. Behner beneficially owns 3,225 shares via this option, held directly.
MiNK Therapeutics insider grant to director Brian Corvese: The filing reports a stock option grant awarding the Reporting Person the right to buy 3,225 shares of MiNK Therapeutics common stock at an exercise price of $15.36 per share. The transaction date is listed as 09/09/2025 and the option shows an expiration date of 09/09/2035 in the table. The form states the option "vests in full on the one-year anniversary of the date of grant" provided the reporting person continues to serve on the company’s board through that date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.
MiNK Therapeutics director Ulf Wiinberg received a grant of stock options on 09/09/2025 allowing purchase of 3,225 shares of common stock at an exercise price of $15.36 per share. The Form 4 shows the options were acquired (transaction code A) and the reporting person beneficially owns 3,225 shares following the transaction. The option term includes an expiration date shown as 09/09/2035 on the filing, and the filing discloses the option vests in full on the one‑year anniversary of the grant if the director continues to serve on the board through that date. The reporting person is identified as a director and the Form 4 was signed by an attorney‑in‑fact.
MiNK Therapeutics director Barbara Ryan received a stock option grant on 09/09/2025. The option gives the right to buy 3,225 shares of common stock at an exercise price of $15.36 per share, is exercisable beginning 09/09/2025, and expires 09/09/2035. The option vests in full on the one-year anniversary of the grant date if the reporting person continues to serve on the board. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/11/2025.
Ulf Wiinberg, a director of MiNK Therapeutics, Inc. (INKT), reported a grant and his current holdings. On 09/02/2025 Mr. Wiinberg was granted 1,011 restricted stock units (RSUs) received in lieu of cash board and committee retainers; the RSUs vest one month from the grant date and are valued at $13.86 per share on the filing. Following the grant he beneficially owns 18,971 shares directly and 27,830 shares indirectly held in an irrevocable trust for his family.
MiNK Therapeutics director Robert Peter Kadlec was granted 975 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. The RSUs, received in lieu of cash retainers, represent a contingent right to one share of common stock per RSU and will vest one month from the grant date. Following the award, the reporting person beneficially owns 17,908 shares. The transaction is reported on Form 4 for ticker INKT and was signed by an attorney-in-fact on 09/03/2025.